CELG-RI
BRISTOL MYERS SQUIBB CO
NYSE · Healthcare · Drug Manufacturers - General · US
$0.12
+9.71%Year over year
Reported trailing growth
- Revenue
- +4.2%
- EBITDA
- +1.1%
- EBIT
- -5.5%
- EPS
- +52.4%
- Free cash flow
- -39.3%
- Operating cash flow
- -35.9%
Forward estimates
Based on analyst estimates
- Revenue
- -4.7%
- EBITDA
- +21.4%
- EPS
- +37.5%
Three-year CAGR
- Revenue
- +1.4%
- EBITDA
- -7.5%
- EBIT
- +14.7%
- Net income
- +3.7%
- EPS
- +5.2%
- Free cash flow
- +2.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026